Merz North American appointed David Dobrowski Vice President and Head of North American Research and Development, effective immediately. In this role, Mr. Dobrowski is responsible for all medical, regulatory, and product safety functions for Merz in North America. He leads the planning and execution of all clinical and pre-clinical development programs in North America and serves as the Global lead on all of Merz‘s research and development activities relating to medical dermatology.

Mr. Dobrowski will join Merz’s North American Leadership Team and will continue to report directly to Bill Humphries, President and CEO of Merz North America. He will also have a reporting relationship to Stefan Albrecht, Global CSO – Merz Pharma Group, in order to ensure alignment with Merz’s global R&D function.

“Since joining Merz, David has established a track record of delivering consistently excellent results, as evidenced by the recent U.S. FDA approvals of Radiesse^® (+) with integral lidocaine and Radiesse^® for use in the hands,“ said Bill Humphries, President and CEO of Merz North America, Inc. “We are confident that David‘s leadership and professionalism will remain key to our ongoing success in North America, and that he and his team continue to make critical contributions across all areas of our business.“

Mr. Dobrowski joined Merz in March 2011 as Director, Regulatory Affairs and most recently served as Vice President, Regulatory Affairs and Product Safety. He brings more than 23 years of experience in the pharmaceutical and medical device space to his new role as Vice President and Head of North American Research and Development. Prior to joining Merz, Dobrowski held roles of increasing responsibility at Salix Pharmaceuticals, UCB Biosciences, Wyeth and Novartis; he has a breadth of experience across multiple specialties, including aesthetics, dermatology, CNS, gastroenterology and opthalmics. Dobrowski holds a Bachelor of Science degree from University of North Carolina at Wilmington. He is a member of the Regulatory Affairs Professional Society (RAPS), Drug Information Association (DIA) and the North Carolina Regulatory Affairs Forum (NCRAF).

In addition, Merz has also announced that Greg B. Bass, who previously held the role of Vice President – Managed Markets, will also assume responsibility for the Merz Dermatology business unit in the U.S. As Vice President – Managed Markets and Medical Dermatology, Bass will remain a member of Merz’s North American Leadership Team and will continue to report directly to Bill Humphries, President and CEO of Merz North America, Inc.